Abstract
The human deacetylase SIRT2 is believed to promote neurodegeneration with recent studies demonstrating that a reduction in the activity of SIRT2 can rescue alpha synuclein toxicity in Parkinson's disease models. In contrast, a second member of the sirtuin family, SIRT1, is believed to play a neuroprotective role. This dichotomy places an additional challenge in the path of sirtuin inhibitor development as a need for isozyme selectivity arises. By combining computational methods with assessment of the biological activity of novel N1-substituted cambinol analogues, further insights that are relevant to this challenge are obtained.
Original language | English |
---|---|
Pages (from-to) | 611-615 |
Number of pages | 5 |
Journal | MedChemComm |
Volume | 2 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2011 |
Keywords
- ENZYMES